Correlation between the Human Development Index and the Incidence and Mortality of Non-Hodgkin Lymphoma

Abstract

Objective

This study was to examine the relationship between socioeconomic status and the incidence and mortality of non-Hodgkin lymphoma (NHL).

Methods

We compared the age-standardized incidence rate (ASIR), age-standardized mortality rate (ASMR), and the ASMR to ASIR ratio (MIR) at national and regional levels and studied the correlation between the MIR and the human development index (HDI) in 2012 and 2018.

Results

The highest ASIR was in North America in 2012 and in Australia in 2018, and the lowest ASIR was in Central and South Asia in both 2012 and 2018. The highest ASMR was in North Africa in both 2012 and 2018, and the lowest ASMR was in Eastern Asia and South-Central Asia in 2012 and in South-Central Asia in 2018. The lowest MIR was in Australia in both 2012 and 2018, and the highest MIR was in Western Africa in both 2012 and 2018. HDI was strongly negatively correlated with MIR (r: −0.8810, P<0.0001, 2012; r: −0.8895, P<0.0001, 2018). Compared to the 2012 data, the MIR in the intermediate HDI countries significantly deceased and the HDI in low and high HDI countries significantly increased in 2018.

Conclusion

The MIR is negatively correlated with HDI. Increasing the HDI in low and intermediate HDI countries may reduce the MIR and increase the survival of patients with NHL.

Keywords

non-Hodgkin lymphoma / incidence / mortality / human development index

References

[1] SullivanR, PeppercornJ, SikoraK, et al.. Delivering affordable cancer care in high-income countries. Lancet Oncol, 2011, 12(10): 933-980

[2] JemalA, BrayF, CenterMM, et al.. Global cancer statistics. CA Cancer J Clin, 2011, 61(2): 69-90

[3] RiesLAG, SmithMA, GurneyJG, et al.Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975–1995, 1999, Bethesda, MD., National Cancer Institute[C]

[4] AkaP, KawiraE, MasaluN, et al.. Incidence and trends in Burkitt lymphoma in northern Tanzania from 2000 to 2009. Pediatr Blood Cancer, 2012, 59(7): 1234-1238

[5] GrossTG, BiondiA. Paediatric non-Hodgkin lymphoma in low and middle income countries. Br J Haematol, 2016, 173(4): 651-654

[6] SmithMA, AltekruseSF, AdamsonPC, et al.. Declining childhood and adolescent cancer mortality. Cancer, 2014, 120(16): 2497-2506

[7] KebudiR, AlkayaDU. Epidemiology and survival of childhood cancer in Turkey. Pediatr Blood Cancer, 2021, 68(2): e28754

[8] ChoeyprasertW, AnurathapanU, PakakasamaS, et al.. Pediatric non-Hodgkin lymphoma: Characteristics, stratification, and treatment at a single institute in Thailand. Pediatri Int, 2019, 61(1): 49-57

[9] ReedijkA, BeishuizenA, CoeberghJ, et al.. Progress against non-Hodgkin’s lymphoma in children and young adolescents in the Netherlands since 1990: Stable incidence, improved survival and lower mortality. Eur J Cancer, 2022, 163: 140-151

[10] FiscellaK, FranksP, GoldMR, et al.. Inequality in quality: Addressing socioeconomic, racial, and ethnic disparities in health care. JAMA, 2000, 283(19): 2579-2584

[11] BetancourtJR, GreenAR, CarrilloJE, et al.. Defining cultural competence: A practical framework for addressing racial/ethnic disparities in health and health care. Public Health Reports, 2003, 118(4): 293-302

[12] Human Development Index[EB/OL]. [December 20]. http://hdr.undp.org/en/statistics/indices/hdi

[13] GiebelS, LabopinM, EhningerG, et al.. Association of Human Development Index with rates and outcomes of hematopoietic stem cell transplantation for patients with acute leukemia. Blood, 2010, 116(1): 122-128

[14] FerlayJ, SoerjomataramI, DikshitR, et al.. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015, 136(5): E359-E386

[15] CANCER TODAY. Data visualization tools for exploring the global cancer burden in 2018[EB/OL]. http://gco.iarc.fr/today/home

[16] United Nations Development Programme Somalia. Somalia Human Development Report 2012. 2012. http://hdr.undp.org/sites/default/files/reports/242/somalia_report_2012.pdf

[17] United Nations Development Programme. Human Development Report 2015. http://hdr.undp.org/sites/default/files/2015_human_development_report.pdf

[18] FidlerMM, SoerjomataramI, BrayF. A global view on cancer incidence and national levels of the human development index. Int J Cancer, 2016, 139(11): 2436-2446

[19] ZhouL, DengY, LiN, et al.. Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: Estimates from the 2017 Global Burden of Disease study. J Hematol Oncol, 2019, 12(1): 107

[20] KhodamoradiF, PakzadR, GhonchehM, et al.. Epidemiology, incidence and mortality of Hodgkin’s cancer in the world and its relation with development. WCRJ, 2018, 5(2): e1085

[21] TorreLA, BrayF, SiegelRL, et al.. Global cancer statistics, 2012. CA Cancer J Clin, 2015, 65(2): 87-108

[22] MagrathI, EpelmanS. Cancer in adolescents and young adults in countries with limited resources. Curr Oncol Rep, 2013, 15(4): 332-346

[23] SankaranarayananR, BlackRJ, SwaminathanR, et al.. An overview of cancer survival in developing countries: Cancer survival in developing countries, Lyon, 1998. IARC, 1998, 145: 135-173

[24] GelbandH, SankaranarayananR, GauvreauCL, et al.. Costs, affordability, and feasibility of an essential package of cancer control interventions in low-income and middle-income countries: Key messages from Disease Control Priorities, 3rd edition. Lancet, 2016, 387(10033): 2133-2144

[25] HébertJR, DaguiseVG, HurleyDM, et al.. Mapping cancer mortality-to-incidence ratios to illustrate racial and sex disparities in a high-risk population. Cancer, 2009, 115(11): 2539-2552

[26] AsadzadehVF, Karim-KosHE, Janssen-HeijnenML, et al.. The validity of the mortality to incidence ratio as a proxy for site-specific cancer survival. Eur J Public Health, 2011, 21(5): 573-577

[27] HuQD, ZhangQ, ChenW, et al.. Human development index is associated with mortality-to-incidence ratios of gastrointestinal cancers. World J Gastroenterol, 2013, 19(32): 5261-5270

[28] PatelAR, PrasadSM, ShihYC, et al.. The association of the human development index with global kidney cancer incidence and mortality. J Urol, 2012, 187(6): 1978-1983

[29] HoneT, MirelmanAJ, RasellaD, et al.. Effect of economic recession and impact of health and social protection expenditures on adult mortality: A longitudinal analysis of 5565 Brazilian municipalities. Lancet Global Health, 2019, 7(11): e1575-e1583

[30] MaruthappuM, WatkinsJ, NoorAM, et al.. Economic downturns, universal health coverage, and cancer mortality in high-income and middle-income countries, 1990–2010: A longitudinal analysis. Lancet, 2016, 388(10045): 684-695

[31] ZengH, ChenW, ZhengR, et al.. Changing cancer survival in China during 2003–15: A pooled analysis of 17 population-based cancer registries. Lancet Global Health, 2018, 6(5): e555-e567

[32] SchellCO, ReillyM, RoslingH, et al.. Socioeconomic determinants of infant mortality: A worldwide study of 152 low-, middle-, and high-income countries. Scand J Public Health, 2007, 35(3): 288-297

[33] FiscellaK, FranksP, GoldMR, et al.. Inequality in quality: Addressing socioeconomic, racial, and ethnic disparities in health care. JAMA, 2000, 283(19): 2579-2584

[34] MurraySA, GrantE, GrantA, et al.. Dying from cancer in developed and developing countries: Lessons from two qualitative interview studies of patients and their carers. BMJ, 2003, 326(7385): 368

[35] JonesLA, ChiltonJA, HajekRA, et al.. Between and within: International perspectives on cancer and health disparities. J Clin Oncol, 2006, 24(14): 2204-2208